All In Biotech

Drug Trial Radar · NCT05904717

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

A Phase 2a, Multi Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of 12 Weeks Treatment With Oral PXS-4728A on Microglia Activation, as Measured by Positron Emission Tomography, in Participants With Isolated Rapid Eye Movement Sleep Behavior Disorder

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Nov 8, 2023

Primary completion

Jul 31, 2026

Study completion Sep 14, 2026

Sponsor

Lead sponsor
SyntaraIndustry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to investigate the safety and efficacy of PXS-4728A as an intervention therapy in participants with iRBD. This study will be conducted in participants aged 50 to 80 years of age and will investigate a single dose level.

Conditions

  • REM Sleep Behavior Disorder

Interventions

  • PXS-4728 (A)Drug

    Participants will receive once daily (QD) for period of 12 weeks

  • Matching Placebo (B)Drug

    Participants will receive once daily (QD) for period of 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the reduction of microglial activation across striato-cortical regionsTime frame: Up to Week 12
  2. To assess the safety and tolerability of PXS-4728A as determined by adverse events (AEs)Time frame: Up to Week 24

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Parkinsons Disease Research Clinic - Macquarie University

    Macquarie, New South Wales, Australia

  • Cognitive Neuroscience Brain & Mind Centre

    Camperdown, Sydney, Australia

  • Clinical Neuroscience Nuffield Department of Clinical Neurosciences

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.